A Phase 2 interventional study of Esketamine DPI - low dose and Esketamine DPI - medium dose in Major Depressive Disorder, sponsored by Celon Pharma SA. Completed at 12 sites in Poland. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-04-28.
Sponsored by Celon Pharma SA · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies in Depressive Disorder, Major with a site in Poland — 15 open to participants now, 17 under way, 10 of them phase 3. Depressive Disorder, Major · Poland.
Among the 86 studies in Depressive Disorder, Major with a site in Poland, this one is the 74th largest by enrollment of the 82 interventional ones that give a count, is one of 7 that started in 2019, is one of 20 in phase 2, and was the 44th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →15 of the 86 studies in Depressive Disorder, Major with a site in Poland are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Poland, United States, Australia and 12 more countries
Ages 18–75
Eli Lilly and Company · Sites in Poland, United States, Australia and 12 more countries
Ages 18–75
Draig Therapeutics Ltd · Sites in Poland, United States, Bulgaria and 2 more countries
Ages 18–75
Aziende Chimiche Riunite Angelini Francesco S.p.A · Sites in Poland
Ages 55+
Cybin IRL Limited · Sites in Poland, United States, Australia and 5 more countries
Ages 18–85
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 22 · Phase 3 55 · Phase 4 4
First in 2003; this study’s year is marked. 7 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 88 is close to the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 464 across the 82 interventional studies, 100 across the 4 observational. Of the 67 that completed or were terminated, 46 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
79 of 86 have an industry lead sponsor. The 10 most frequent:
Celon Pharma SA is the lead sponsor of 11 studies on the registry; none are open to participants now.
Celon Pharma SA has 1 study filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
9 of the studies in Depressive Disorder, Major with a site in Poland that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
| NCT06922110Phase 3Xenon Pharmaceuticals Inc.An Open-Label Study of Azetukalner in Major Depressive Disorder | 2027-01 |
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
| NCT06793397Phase 3Cybin IRL LimitedA Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | 2027-06-07 |
| NCT07377682Aziende Chimiche Riunite Angelini Francesco S.p.AReal-world Clinical Response to Trazodone in Italy, Poland, and Romania | 2026-12 |
Add all 9 to your calendar (.ics) → With an account.
Among the 86 studies in Depressive Disorder, Major with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine the efficacy, safety and pharmacokinetics of inhaled Esketamine in participants with treatment-resistant depression (TRD) in the course of Major Depressive Disorder (MDD). The study is to determine the efficacy and dose response of three Esketamine doses, compared with placebo.
This is a randomized, multiple dose, placebo-controlled, double-blind, multicentre study of Esketamine DPI, inhalation powder delivered via dry powder inhaler (DPI) in participants with TRD in the course of MDD. There are 3 study phases: Screening phase, a two weeks double-blind treatment phase and a 6-week follow-up phase. Participants are to be randomized in 1:1:1:1 ratio to receive placebo or one of the three doses of Esketamine DPI. Participants from each group will receive different dosing sequences, consider as a single dose, corresponding to low, medium, high Esketamine dose or placebo. Participants will undergo one cycle of treatment consisting of four doses of Esketamine DPI or placebo over 14-day period. Participants safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
Drug: Esketamine DPI - low dose
Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
Drug: Esketamine DPI - medium dose
Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
Drug: Esketamine DPI - high dose
Participants are to receive four doses of Placebo DPI administered over 14-day period (on Day 1, 4, 8 and 11).
Drug: Placebo DPI
Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to low Esketamine dose.
Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to medium Esketamine dose.
Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to high Esketamine dose.
Placebo DPI is to be administered via dry powder inhaler.
Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score at Day 14
The MADRS is a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. The test consists of 10 items, each scored from 0 (symptoms not present or normal) to 6 (severe or continuous presence of the symptoms). Total score is 60. The higher MADRS total score, the more severe depression.
Time frame: Day 1 and Day 14
Change from baseline in MADRS total score at each other than Day 14 timepoint
The MADRS is a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. The test consists of 10 items, each scored from 0 (symptoms not present or normal) to 6 (severe or continuous presence of the symptoms). Total score is 60. The higher MADRS total score, the more severe depression.
Time frame: Day 1, 2, 4, 5, 8, 9, 11, 12 and week 3, 4, 5, 6, 7 and 8
Number of participants with clinical response (>= 50% decrease in MADRS baseline score)
Clinical response is to be defined as greater than or equal to 50 % decrease in MADRS baseline score at Day 14 and every other timepoint.
Time frame: Day 1, 2, 4, 5, 8, 9, 11, 12, 14 and up to 6 weeks after the treatment phase
Onset of clinical response that was sustained through the end of the 2-week, double-blind, treatment phase
Time frame: Day 1, 2, 4, 5, 8, 9, 11, 12, 14
Change from baseline in depression severity, measured by Hamilton Depression Rating Scale (HDRS) at every timepoint
HDRS is a questionnaire used to rate the severity of depression by probing mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss and somatic symptoms. HDRS consists of 17 questions with maximum 4-points scale. The higher HDRS total score, the more severe depression.
Time frame: Day 1, 2, 4, 5, 8, 9, 11, 12, 14 and week 3, 4, 5, 6, 7 and 8
Number of participants with clinical remission (MADRS total score <= 10)
Clinical remission, defined as MADRS total score less than or equal to 10.
Time frame: Day 1, 2, 4, 5, 8, 9, 11, 12, 14 and up to 6 weeks after the treatment phase
Time to relapse
Relapse assessed for responders and remitters and defined when MADRS total score in 2 consecutive assessments after Day 14 exceeds 50% MADRS baseline total score value.
Time frame: Day 14 and week 3, 4, 5, 6, 7 and 8
Change from baseline in Clinical Global Impression - Severity (CGI-S) score at Day 14 and every other timepoint
CGI-S scale is a physician-rated scale that is designed to rate the severity of the patient's illness at the time of assessment. It is a 7-point assessment where 1 = normal (not at all ill) and 7 = among the most extremely ill patients.
Time frame: Day 1, 2, 4, 5, 8, 9, 11, 12, 14 and week 3, 4, 5, 6, 7 and 8
Change from baseline in Columbia Suicide Severity Rating Scale (C-SSRS) at Day 14 and every other timepoint
C-SSRS is a suicide ideation rating scale created by researchers at Columbia University.
Time frame: Day 1, 14 and week 5, 8
Change from baseline in the Clinician Administered Dissociative States Scale (CADSS) at each day of administration
CADSS is a scale designed to assess dissociative symptoms. CADSS consists of 23 questions with 4-points scale, where 1=normal (not at all) and 4=Extremely. The higher CADSS total score, the more severe symptoms.
Time frame: up to 24 hours following the start of each administration
Change from baseline in the Brief Psychiatric Rating Scale (BPRS) at each day of administration
BPRS is a scale designed to rate psychotomimetic effects. BPRS consists of 18 questions with 7-points scale, from 1 (not present) to 7 (extremaly severe). The higher BPRS total score, the more severe effects.
Time frame: up to 24 hours following the start of each administration
Potential withdrawal symptoms after Esketamine treatment, as measured by the 20-item Physician Withdrawal Checklist (PWC-20)
PWC-20 is a method to assess discontinuation symptoms.
Time frame: Day 0, week 3, 4 and 5
Potential Esketamine effect on cognition as measured by Montreal Cognitive Assessment (MoCA)
MoCA is a screening assessment for detecting cognitive impairment.
Time frame: Day 0, week 4 and 8
Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: up to 8 weeks
Esketamine AUC0-24h - area under the plasma concentration - time curve from time 0 to 24 h
Time frame: up to 24 hours following the start of first and fourth administration
Esketamine Cmax - maximum plasma concentration
Time frame: up to 24 hours following the start of first and fourth administration
Esketamine AUC0-inf - area under the plasma concentration - time curve from time 0 to infinity
Time frame: up to 24 hours following the start of first and fourth administration
Esketamine Kel - terminal elimination rate constant
Time frame: up to 24 hours following the start of first and fourth administration
Esketamine t1/2 - plasma elimination half-life
Time frame: up to 24 hours following the start of first and fourth administration
Esketamine Tmax - time to reach maximum concentration in plasma
Time frame: up to 24 hours following the start of first and fourth administration
Esnorketamine AUC0-24h - area under the plasma concentration - time curve from time 0 to 24 h
Time frame: up to 24 hours following the start of first and fourth administration
Esnorketamine Cmax - maximum plasma concentration
Time frame: up to 24 hours following the start of first and fourth administration
Esnorketamine Tmax - time to reach maximum concentration in plasma
Time frame: up to 24 hours following the start of first and fourth administration
Changes between predose and postdose values for each administration in hematology and biochemistry
Time frame: up to 6 weeks
Changes between predose and postdose values for each administration in vital signs (heart rate, blood pressure, respiratory rate) and urinalysis
Time frame: up to 8 weeks
Changes between predose and postdose values for each administration in SpO2 (blood oxygen saturation)
Time frame: up to 2 hours following the start of each administration
Ran from Feb 2019 to primary completion in Mar 2020, 12 months.
Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 12 months is below that.
Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Celon Pharma SA